

**VIVALIS AND BOEHRINGER INGELHEIM ANIMAL HEALTH  
SIGN A RESEARCH LICENSE AGREEMENT, WITH AN OPTION TO ENTER  
INTO A COMMERCIAL LICENSE AGREEMENT TO USE EB66<sup>®</sup> PLATFORM  
FOR VETERINARY VACCINES PRODUCTION**

**Nantes, France – February 17, 2009 – VIVALIS (NYSE Euronext: VLS) and BOEHRINGER INGELHEIM Animal Health**, the animal health division of the global pharmaceutical company BOEHRINGER INGELHEIM, headquartered in Germany, announced today the signing of a research license agreement to use the EB66<sup>®</sup> cell line, proprietary of Vivalis, for the production of several veterinary vaccines. The Agreement includes an option to enter into a commercial license agreement to use this cell line platform for production of vaccines to protect animals.

*"Vivalis is pleased to enter into this new research agreement with one of the major players in the field of veterinary vaccines. This 24<sup>th</sup> license confirms that VIVALIS EB66<sup>®</sup> cell line is a very attractive alternative to embryonated eggs for the industrial production of vaccines both for human and animal health", said Franck Grimaud, Vivalis CEO.*

Terms of the agreement were not disclosed.

**About the EB66<sup>®</sup> cell line**

EB66<sup>®</sup> cell line, derived from duck stem cells, presents unique industrial and regulatory characteristics such as long term genetic stability, immortality and cell growth to high cell densities (>20 million cells/mL) in suspension, in serum free medium.

The BMF (Biologics Master File) for the registration of the EB66<sup>®</sup> cell line with the FDA (Food and Drug Administration) has been filed on June 27th, 2008.

EB66<sup>®</sup> cell line is currently used or tested by 75% of the world players in vaccines. With 24 licenses signed today, the EB66<sup>®</sup> cell line is becoming a new standard cell substrate for biologics production.

\*\*\*\*\*

**Next financial press release:**

**March 31, 2009, after NYSE Euronext market closing: 2008 annual results**

## **About Vivalis**

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS' expertise and intellectual property are exploited in three main areas:

1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck stem cells, to pharmaceutical and biotechnology companies for the production of vaccines. Vivalis receives up front, milestones, and royalties on its licensees' net sales.
2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licenses its EB66® cell line for the production of recombinant proteins to biotechnology and pharmaceutical companies. Vivalis receives up front, milestones, and royalties on its licensees' net sales.
3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES bio-cluster.

Learn more about Vivalis at [www.vivalis.com](http://www.vivalis.com)

### **Practical Information about Vivalis shares:**

Listed on Euronext Paris – Compartment C of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext's Next Biotech index

### **Contact:**

Vivalis, France

Franck Grimaud

CEO

[investors@vivalis.com](mailto:investors@vivalis.com)

### **NewCap:**

Financial communication Agency

Steve Grobet/Emmanuel Huynh

Phone: +33 (0)1 44 71 94 91

[vivalis@newcap.fr](mailto:vivalis@newcap.fr)